title: Dexamethasone Intravitreal Implant in the Treatment of Uveitic Macular Edema in the Perioperative Cataract Setting: A Case Series.
abstract: OBJECTIVE
  To examine the efficacy of the dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc, Irvine, California, USA) in the control of uveitic macular edema in the perioperative setting of cataract surgery.
  
  
  METHODS
  Retrospective observational case series.
  
  
  METHODS
  setting: Clinical practice.
  
  
  METHODS
  A total of 17 eyes of 14 patients that received a DEX implant for cystoids macular edema (CME) associated with noninfectious uveitis who underwent subsequent phacoemulsification within 4 months.
  
  
  METHODS
  Each patient was treated with a DEX 0.7 mg intravitreal implant and underwent phacoemulsification with intraocular lens placement.
  
  
  METHODS
  Primary outcome measure was the change in central macular thickness (CMT) measured by optical coherence tomography (OCT), measured preoperatively and postoperatively.
  
  
  RESULTS
  Seventeen eyes (14 patients) were included for analysis. There was no statistically significant change from preoperative CMT (mean 302 μm) to postoperative CMT (307 μm) on OCT. In the subset of eyes that underwent phacoemulsification within 4 weeks of the DEX implant (8 eyes), the mean change in CMT was -47.0 μm, compared to +51.1 μm in those that received the DEX implant greater than 4 weeks prior to phacoemulsification (P = .005).
  
  
  CONCLUSIONS
  Intravitreal dexamethasone implant was shown to prevent the recurrence or worsening of macular edema in uveitic patients with a history of CME who underwent phacoemulsification. The mean CMT decreased in the subset of eyes that received the DEX implant within 4 weeks prior to cataract surgery.
authors.affiliation: Department of Ophthalmology, University of Colorado, Aurora, Colorado.
authors.forename: Marissa Bucci
authors.initials: MB
authors.lastname: Larochelle
authors.affiliation: Department of Ophthalmology, Emory University, Atlanta, Georgia.
authors.forename: Jesse
authors.initials: J
authors.lastname: Smith
authors.affiliation: Colorado Retina Associates, Denver, Colorado. Electronic address: mdacey@retinacolorado.com.
authors.forename: Mark S
authors.initials: MS
authors.lastname: Dacey
mesh_terms: D000328:Adult; D000368:Aged; D002386:Cataract / Q000150:complications*; D003907:Dexamethasone / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D019654:Lens Implantation, Intraocular; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification; D011183:Postoperative Complications; D012008:Recurrence; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014792:Visual Acuity
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone